Assignee
FACET BIOTECH CORP
US·14 granted patents·6 pending applications·191 citations·filing 2004–2010
Top patents by PatentIndex Score
20 records- 0196US7732570B2Alteration of Fc-fusion protein serum half-lives by mutagenesisFACET BIOTECH CORP·Filed 2007·Granted Jun 8, 2010·26 cites·4 claims
- 0293US7709610B2Therapeutic use of anti-CS1 antibodiesFACET BIOTECH CORP·Filed 2004·Granted May 4, 2010·40 cites·26 claims
- 0393US7592004B2Stable lyophilized pharmaceutical formulation of IgG antibodiesFACET BIOTECH CORP·Filed 2005·Granted Sep 22, 2009·57 cites·10 claims
- 0491US7732195B2Tethered vectors for cell surface immunoglobulin displayFACET BIOTECH CORP·Filed 2007·Granted Jun 8, 2010·21 cites·22 claims
- 0591US7674883B2Antibodies against cancer antigen TMEFF2 and uses thereofFACET BIOTECH CORP·Filed 2007·Granted Mar 9, 2010·6 cites·14 claims
- 0691US7662384B2Use of anti-α5β1 antibodies to inhibit cancer cell proliferationFACET BIOTECH CORP·Filed 2005·Granted Feb 16, 2010·21 cites·13 claims
- 0787US7842293B2Compositions and methods using anti-CS1 antibodies to treat multiple myelomaFACET BIOTECH CORP·Filed 2007·Granted Nov 30, 2010·7 cites·7 claims
- 0887US7807163B2Antibodies against GPR64 and uses thereofFACET BIOTECH CORP·Filed 2008·Granted Oct 5, 2010·7 cites·37 claims
- 0984US7824678B2Antibodies against cancer antigen TMEFF2 and uses thereofFACET BIOTECH CORP·Filed 2007·Granted Nov 2, 2010·4 cites·9 claims
- 1081US7785816B2Antibodies against cancer antigen TMEFF2 and uses thereofFACET BIOTECH CORP·Filed 2007·Granted Aug 31, 2010·2 cites·4 claims
- 1168US7914789B2HEMCM42 antibodiesFACET BIOTECH CORP·Filed 2007·Granted Mar 29, 2011·0 cites·9 claims
- 1268US2010074841A1Compositions Against Cancer Antigen LIV-1 and Uses ThereofFACET BIOTECH CORP·Filed 2009·Application pending·0 cites
- 1364US7879987B2Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesisFACET BIOTECH CORP·Filed 2007·Granted Feb 1, 2011·0 cites·11 claims
- 1464US7776585B2Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesisFACET BIOTECH CORP·Filed 2007·Granted Aug 17, 2010·0 cites·11 claims
- 1564US7547544B2Antibodies against GPR64 and uses thereofFACET BIOTECH CORP·Filed 2007·Granted Jun 16, 2009·0 cites·18 claims
- 1653US2010055098A1Method for treating multiple sclerosis patients with anti-il2r antibodiesFACET BIOTECH CORP·Filed 2009·Application pending·0 cites
- 1751US2011165154A1Compositions and methods using anti-cs1 antibodies to treat multiple myelomaFACET BIOTECH CORP·Filed 2010·Application pending·0 cites
- 1836US2011104153A1Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patientsFACET BIOTECH CORP·Filed 2010·Application pending·0 cites
- 1936US2011053209A1Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patientsFACET BIOTECH CORP·Filed 2010·Application pending·0 cites
- 2035US2010273204A1Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patientsFACET BIOTECH CORP·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when FACET BIOTECH CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →